| Literature DB >> 21290178 |
John D Guerry1, Paul D Hastings.
Abstract
Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in adults with major depressive disorder is among the most consistent and robust biological findings in psychiatry. Given the importance of the adolescent transition to the development and recurrence of depressive phenomena over the lifespan, it is important to have an integrative perspective on research investigating the various components of HPA axis functioning among depressed young people. The present narrative review synthesizes evidence from the following five categories of studies conducted with children and adolescents: (1) those examining the HPA system's response to the dexamethasone suppression test (DST); (2) those assessing basal HPA axis functioning; (3) those administering corticotropin-releasing hormone (CRH) challenge; (4) those incorporating psychological probes of the HPA axis; and (5) those examining HPA axis functioning in children of depressed mothers. Evidence is generally consistent with models of developmental psychopathology that hypothesize that atypical HPA axis functioning precedes the emergence of clinical levels of depression and that the HPA axis becomes increasingly dysregulated from child to adult manifestations of depression. Multidisciplinary approaches and longitudinal research designs that extend across development are needed to more clearly and usefully elucidate the role of the HPA axis in depression.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21290178 PMCID: PMC3095794 DOI: 10.1007/s10567-011-0084-5
Source DB: PubMed Journal: Clin Child Fam Psychol Rev ISSN: 1096-4037
Dexamethasone suppression test studies with children and adolecents
| Study | MDD | Control | MDD measure | Dose | Collection method/time | Non-suppressors | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Livingston et al. | 3 MDD (1 pure, 2 comorbid with DD, CD, etc.) | 12 PC | Dx assigned at clinical case conference | 0.5 mg @ 11 pm | Venipuncture @ 4 p.m. next day | 2/3 MDD 4/6 ANX 1/1 SZ-S 0/3 CD 0/2 MISC | 67 | 58 |
| Petty et al. | 7 MDD (3 pure, remainder comorbid with CD, aggressive behavior, etc.) | 23 PC | “Consensus dx” assigned using DSM-III criteria; KSADS-E administered for 60% across all groups | 0.5 mg @ 11 pm | Venipuncture @ 4 pm next day, 2/3 of all patients also had 11 pm venipuncture | 6/7 MDD 4/5 DD 5/6 SZ-S 1/3 CD 2/3 ANX 1/6 MISC | 86 | 43 |
| Casat et al. | 11 MDD (unknown comorbidity status) | 9 PC | Dx assigned by K-SADS-E using DSM-III-R criteria | 2 trials: 0.5 mg @ 11 pm on Days 1 and 6 | Venipuncture @ 8 am and 4 pm on Days 2 and 7 |
| 27/18 | 44/66 |
| Pfeffer et al. | 20 MDD (unknown comorbidity status) | 31 PC | Dx assigned by 2 independent parent and child K-SADS-P, consensus dx made using DSM-III criteria | 0.5 mg @ 11 pm | Venipuncture @ 8 am, 4, and 11 pm next day | 11/20 MDD 4/31 PC | 55 | 87 |
| Pfeffer et al. | 19 MDD (unknown comorbidity status) | As above | As above | 1 mg @ 11 pm | As above | 2/19 MDD 1/31 PC | 11 | 97 |
| Fristad et al. ( | 63 MDD (unknown comorbidity status) | 14 PC 21 NC | DICA, CDI administered w/child and parents | 0.5 mg @ 11 pm | Venipuncture next day @ 8 am and 4 pm | Either time: 42/63 MDD 1/14 PC 2/21 NC | 67 | 91 |
| Naylor et al. | 14 MDD (unknown comorbidity status), 11 DD | 48 PC | “Consensus dx” assigned after 2 weeks of hospitalization based on DSM-III criteria | 0.5 mg @ 11 pm if < 36 kg 1 mg @ 11 pm if > 36 kg | Venipuncture @ 4 pm next day | 7/25 MDD + DD 11/48 PC | 28 | 77 |
| Doherty et al. | 59 MDD (19 pure, remainder comorbid) | 34 PC | Dx assigned by DSM-III criteria following “Standard clinical assessment” | 1 mg @ 11 pm | Venipuncture next day @ 8 am, 4 pm, and 11 pm | 15/34 MDD 4/19 DD 2/6 ADDM 1/15 ANX 0/4 CD 0/8 SZ-S 0/7 MISC | 44 | 88 |
| Weller et al. | 20 MDD (unknown comorbidity status) | N/A | Unknown | 0.5 mg @ 11 pm | Venipuncture next day @ 8 am and 4 pm | 14/20 MDD | 70 | N/A |
| Freeman et al. | 5 MDD (comorbid w/SZ-S) | N/A | Child, parent KSADS | 0.5 mg @ 11 pm | Venipuncture next day @ 4 pm | 4/5 MDD | 80 | N/A |
| Weller et al. | 50 MDD (unknown comorbiditystatus) | 18 PC 18 NC | DICA, DSM-III | 0.5 mg @ 11 pm | Venipuncture next day @ 8 am and 4 pm | 41/50 MDD 5/18 BD 2/18 NC | 82 | 72 PC 89 NC |
| Livingston and Martin-Cannici | 8 MDD (significant comorbid ANX) | 12 ANX 12 BD | Child, parent DICA | 0.5 mg @ 11 pm | Venipuncture next day @ 4 pm | 8/8 MDD 8/12 ANX 1/12 BD | 100 | 63 |
|
| ||||||||
| Young et al. ( | 3 MDD; Due to low N only conducted analyses with grouped Dxs (3 MDD, 4 ANX, 3 ODD, 1 ADHD) | 32 NC | K-SADS | 2 trials, randomly assigned: 0.5 mg @ “bedtime” 1 mg @ “bedtime” | Saliva sample next day w/in 45 min of awakening, 4 pm, and “bedtime” | Not reported | Unknown | Unknown |
| Steingard et al. | 27 MDD (comorbidity status unknown), 29 MDD + ADHD | 5 PC | Clinical interviews conducted with child/parent, all dx based on DSM-III criteria | Weight corrected 17 µg/kg @ 11 pm | Venipuncture next day @ 4 pm | 8/27 MDD 11/29 MDD + ADHD 5/22 ADHD 0/5 PC | 34 | 81 |
| Birmaher et al. | 26 MDD (comorbidity status unknown) | 10 PC 8 NC | 2 independent child and parent KSADS-P, MDD Dx assigned by RDC criteria, control dx by DSM-III | 0.25 mg @ 9 pm | Indwelling catheter: 24 hourly samples | 11/26 MDD 2/10 PC 6/8 NC | 42 | 55 overall 80 PC 25 NC |
| Birmaher et al. | 23 MDD (comorbidity status unknown) | 13 PC 9 NC | As above | 0.5 mg @ 9 pm | As above | 4/23 MDD 0/15 PC 5/8 NC | 17 | 78 overall 100 PC 38 NC |
| Poznanski et al. | 9 MDD (comorbidity status unknown) | 9 PC | Dx assigned by “case conference consensus” after parent and child KSADS | 0.5 mg @ 11 pm | Venipuncture next day @ 4 pm | 5/9 MDD 1/9 PC | 56 | 89 |
| Geller et al. | 14 MDD (9 comorbid for antisocial behavior or ANX) | N/A | KSADS-P according to RCD and DSM-III | Weight corrected 20 µg/kg @ 11:30 pm | Venipuncture next day @ 4 pm | 2/14 MDD | 14 | N/A |
|
| ||||||||
| Extein et al. | 15 MDD (all “pure”) | 12 PC | Semistructured interviews, Dx assigned by DSM-III criteria for MDD | 1 mg @ 12 am | Venipuncture next day @ 8 am, noon, 4 pm, and midnight | 8/15 MDD 1/12 PC | 53 | 92 |
| Hsu et al. | 14 MDD (unknown comorbidity status) | 79 PC | Semistructured, standardized intake interview, chart review according to DSM-III criteria | 1 mg @ 11 pm | Venipuncture next day @ 4 pm and 11 pm | 9/14 MDD 2/6 ADDM 0/2 DD 4/26 CD 2/8 SZ-S 6/10 ED | 64 | 68 |
| Robbins et al. | 16 MDD (unknown comorbidity status) | 12 PC | “Consensus dx” according to RDC criteria based on K-SADS, Hamilton Rating Scale | 1 mg @ 11 pm | Venipuncture next day @ 8 am, 4 pm, 11 pm | 4/16 MDD 0/12 PC | 25 | 100 |
| Ha et al. ( | 26 (22 MDD, 4 w/”minor depressive d/o”) | 16 PC | Adolescent and parent KSADS | 1 mg @ 11:30 pm | Venipuncture next day @ 4 pm and 11 pm | 7/22 MDD 2/4 DD 3/16 PC | 32 | 75 |
| Targum and Capodanno | 17 MDD (unknown comorbidity status) | 103 PC | Dx assigned according to DSM-III criteria using clinical interview | 1 mg @ 11:30 pm | Venipuncture next day @ 4 pm @ 11:30 pm | 7/17 MDD 7/38 DD 7/47 CD 4/15 SZ-S | 41 | 82 |
| Robbins et al. | 4 MDD | 5 PC | 2 independent KSADS, consensus dx according to RCD criteria | 1 mg @ 11:30 pm | Venipuncture next day @ 8 am, 4 pm, 11 pm | 2/4 MDD 0/5 PC | 50 | 100 |
| Klee and Garfinkel | 20 MDD (unknown comorbidity status) | 13 PC | KSADS dx according to RDC criteria | 1 mg @ 11 pm | Venipuncture next day @ 8 am, 4 pm, 11 pm | 8/20 MDD 1/13 PC | 40 | 92 |
| Emslie et al. ( | 33 MDD (predominantly comorbid) | 18 DD 35 PC | Dx assigned according to DSM-III criteria using semistructured interview w/patients and parents | 0.5 mg for children (< Tanner 3), 1 mg for adolescents | Venipuncture next day @ 4 pm | 18/33 MDD 4/18 DD 4/35 PC | 55 | 89 (PC) |
| Woodside et al. ( | 10 MDD (unknown comorbidity status) | 18 CD 2 BP | Consensus diagnosis according to DSM-III | 1 mg @ 11 pm | Venipuncture next day @ 4 pm and 11 pm | 8/10 MDD 2/18 CD 2/2 BP | 80 | 80 |
| Khan | 33 MDD (predominantly comorbid) | 22 CD 6 DD 5 ADHD | Semistructured interview according to DSM-III | 1 mg @ 11 pm | Venipuncture next day @ 4 pm and 11 pm | 23/33 MDD 3/22 CD 1/6 DD 1/5 ADHD | 70 | 85 |
| Evans et al. | 20 MDD (unknown comorbidity) | 32 PC | Semi-/un-structured interview with patient and family members according to DSM-III criteria | 1 mg @ 11 pm | Venipuncture next day @ 4 pm and 11 pm | 8/20 MDD 5/32 PC | 40 | 84 |
| Appelboom-Fondu and Kerkhofs | 8 MDD (comorbid with bipolar) | 12 PC | KSADS according to RDC criteria | 1 mg @ 9 pm | Venipuncture next day @ 2 and 9 pm | 4/8 MDD 0/12 PC | 50 | 100 |
|
| ||||||||
| Birmaher et al. | 44 MDD (Unknown comorbidity status) | 38 NC | 2 independent K-SADS administered, HAM-D, According to RDC criteria for MDD | 1.0 mg @ 11 pm | Indwelling catheter: hourly samples next day from 8 am - 11 pm | 6/44 MDD 1/38 NC | 14 | 97 |
| Dahl et al. | 27 MDD (significant comorbidity) | 34 NC | 2 independent parent and child KSADS-P, dx based on RDC, DSM-III criteria | 1 mg @ 11 pm | Indwelling catheter: hourly samples next day from 8 am - 11 pm | 4/27 MDD 3/34 NC | 15 | 91 |
ADDM adjustment disorder with depressed mood, ADHD attention-deficit/hyperactivity disorder, ANX anxiety disorders, BD behavior disorders (oppositional defiant disorder, ADHD with hyperactivity, conduct disorder), BP bipolar disorder, CD conduct disorder, DD dysthymic disorder, ED eating disorders, MDD major depressive disorder, MISC miscellaneous diagnoses, NC normative controls, ODD oppositional defiant disorder, PC psychiatric controls, SZ-S schizophrenia spectrum
Studies of basal cortisol functioning in children and adolescents
| Study | Sample | MDD | Control | MDD measure | Collection method/time | Nighttime cortisol | Daytime and/or total cortisol |
|---|---|---|---|---|---|---|---|
| Pfeffer et al. | Inpatient children | 20 MDD (unknown comorbidities) | 19 DD 9 SZ-S 3 Neither | Dx assigned according to DSM-III criteria based on 2 independent K-SADS-P with parents and children | Venipuncture @ 8 am, 4, and 11 pm | Equivalent | Equivalent |
| Casat et al. | Inpatient children | 11 MDD (unknown comorbidities) | 9 PC | Dx assigned according to DSM-III criteria based on K-SADS-E | Venipuncture @ 8 AM on two separate days | N/A | Lower |
| Birmaher et al. | Both inpatient and outpatient children | 34 MDD (unknown comorbidities) | 22 NC | Dx assigned according to RDC based on parent and child K-SADS-P and K-SADS-E | Indwelling venous catheter; samples taken 30, 15, 0 min before 9 am CRH infusion | N/A | Equivalent |
| Kaufman et al. ( | Both inpatient and outpatient children | 13 MDD abused 13 MDD non | 13 NC | Dx assigned according to RDC based on 2 independent K-SADS | Indwelling venous catheter: samples taken at 30, 15, and 0 min pre- CRH infusion | N/A | Equivalent |
| Birmaher et al. | Outpatient children | 23 MDD (15 endogenous, 6 psychotic, 18 suicidal) | 13 PC 9 NC | Dx assigned according to DSM-III (PC) or RDC criteria (MDD) based on 2 independent parent and child KSADS-P | Indwelling catheter: 24 hourly samples beginning 9 PM | Equivalent | Equivalent |
| Feder et al. | Outpatient children | 76 MDD (unknown comorbidities) | 31 ANX 17 NC | Dx assigned according to RDC criteria based on 2 independent K-SADS-P | Indwelling venous catheter: hourly blood samples collected over 24-hr period | Equivalent | Equivalent |
| Luby et al. | Outpatient preschoolers | 55 MDD (unknown comorbidities) | 43 PC 57 NC | Parent DISC (modified to be developmentally appropriate) | Saliva samples collected on 3 consecutive nights | Equivalent | N/A |
| Forbes et al. | Outpatient children and adolescents | 116 MDD (unknown comorbidities) | 32 ANX 76 NC | Dx assigned by case conference consensus based on K-SADS-PL | Indwelling venous catheter: daytime = 40, 20, and 0 min before CRH infusion; nighttime = every 20 min beginning 2 h before individual bedtime | Higher than NC | N/A |
| Puig-Antich et al. | Outpatient children | 45 MDD (unknown comorbidities) | 20 PC 8 NC | Dx assigned according to RDC criteria based on 2 independent K-SADS-Ps | Indwelling venous catheter: samples every 20 min for 24 h | Equivalent | Equivalent |
| Doherty et al. | Inpatient children and adolescents | 43 MDD (significant comorbidity) | 29 PC | Dx assigned according to DSM-III criteria following “Standard clinical assessment” | Venipuncture @ 8 am and 11 pm. | Equivalent | Equivalent |
| Goodyer et al. | Outpatient children and adolescents | 82 MDD (unknown comorbidities) | 11 PC 40 NC | Dx assigned according to DSM-III-R criteria based on K-SADS-P | Salivary cortisol samples at 8 AM, 12 PM, 8 PM over 2 consecutive days | Higher than both PC, NC | Equivalent |
| Extein et al. | Inpatient adolescents | 15 MDD (unknown comorbidities) | 12 PC | Dx assigned according to DSM-III criteria based on semistructured interviews | Venipuncture @ 4 pm, midnight, and 8 am. | Equivalent | Equivalent |
| Kutcher et al. | Inpatients adolescents | 12 MDD (unknown comorbidities) | 12 NC | Dx assigned according to DSM-III-R criteria based on K-SADS | Indwelling venous catheter: samples at 10 PM, 12 AM, 1, 2, 3, 4, and 6 AM | Equivalent | Equivalent |
| Dahl et al. | Inpatient and outpatient adolescents | 27 MDD (“significant comorbidity”) | 32 NC | Dx assigned according to adult RDC criteria based on 2 independent K-SADS-Ps | Indwelling venous catheter: blood draws every 20 min for 24 h (starting 8:30 AM) | Higher | Equivalent |
| Rao et al. | Outpatient adolescents | 30 MDD (unknown comorbidities) | 25 NC | Dx assigned according to DSM-IV criteria based on adolescent and parent K-SADS-PL | Saliva samples collected at 30 min intervals for 2 h (i.e., 5 samples) | N/A | Equivalent |
| Dahl et al. | Outpatient adolescents | 48 MDD (unknown comorbidities) | 40 NC | Dx assigned according to adult RDC criteria based on 2 independent K-SADS-Ps | Indwelling venous catheter: blood samples every 20 min for 24 h | Equivalent | Equivalent |
| Rao and Poland | Outpatient adolescents | 16 MDD (unknown comorbidities) | 16 NC | Dx assigned according to DSM-IV criteria based on adolescent and parent K-SADS-PL | Nocturnal urinary free cortisol (10:30 pm and 7 am samples) | Higher | N/A |
| Mathew et al. | Outpatient adolescents, in 10 year follow-up study | 48 MDD at Time 1; 56 MDD at Time 2 (15 with comorbid anxiety disorder) | 21 NC | Dx assigned according to SADS-LA according to best estimate procedure | Indwelling venous catheter; blood samples every 20 min for 24 h (starting in the A.M.) | Equivalent, but LOWER in subsequently suicidal outpatients | Equivalent, but HIGHER in subsequently suicidal outpatients |
| Goodyer et al. | Outpatient adolescents, in 2 year follow-up study | 30 MDD (19 RMD, 11 PMD) | 30 NC (high risk, never depressed) | Dx assigned according to DSM-IV criteria based on the Kiddie-SADs patient version | Salivary cortisol samples at 8 A.M. and 8 P.M. over 4 consecutive days | Equivalent | Equivalent, but higher morning cortisol:DHEA ratio in PMD |
| Adam et al. | Outpatient adolescents, in 1 year follow-up study | 40 past MDD and 16 current MDD at Time 1; 18 MDD at Time 2 (9 recurrences, 9 new cases); 20 with subclinical MDD at Time 2. | 192 NC (over-sampled for high neuroticism) | Dx assigned according to the DSM-IV (SCID) | Salivary cortisol samples gathered 6 times per day over 3 consecutive weekdays: at wake-up, 40 min after waking, at 3, 8, and 12 h post-awakening, and at bedtime. | Equivalent | Higher (Car) |
ANX anxiety disorders, DD dysthymic disorder, MDD major depressive disorder, NC normal controls, PC psychiatric controls, SZ-S schizophrenia spectrum disorders, RMD remitted major depression, PMD persistent major depression, CAR cortisol awakening response
aGroups were further split into: MDD T1 Suicide (attempts prior to T1), MDD T10 Suicide (attempts between T1 and follow up), and MDD No Suicide. MDD T10 showed elevated cortisol levels prior to sleep onset (afternoon, evening, night). MDD T10 also showed elevated cortisol levels 100 min prior and 100 min after sleep onset, but lower levels of cortisol secretion 2-4 h after sleep onset
bYouths with MDD that persisted over 24 months had higher cortisol:DHEA ratios in morning saliva samples than at-risk youths without depression, and at-risk youths who had MDD at 12 months follow-up but remitted by 24 months
cStudy also used CAR (cortisol awakening response) information as predictor of later onset of MDD, and found that individuals who had higher levels of cortisol in their CAR were more likely to become MDD by follow-up. For these purposes, the 56 baseline MDD participants were excluded from that part of the study